Under the deal, TrilliumBio will offer Oncobit's digital PCR-based uveal melanoma monitoring test through its Rockville, Maryland-based laboratory.

TrilliumBiO and The LAM Foundation join forces to enhance awareness about lymphangioleiomyomatosis (LAM), a rare lung disease impacting women, and improve diagnostic pathways.

TrilliumBiO and Oncobit unveil Oncular™, an innovative monitoring solution for uveal melanoma, enhancing patient care with real-time insights.

TrilliumBiO and Oncobit launch Oncular™, an innovative solution for monitoring uveal melanoma, enhancing patient care through advanced molecular testing.

TrilliumBiO partners with Oncobit to improve uveal melanoma monitoring in the U.S., enhancing patient care with advanced therapeutic insights.

TrilliumBiO collaborates with Oncobit to enhance uveal melanoma monitoring in the U.S., improving patient care through advanced diagnostics.

TrilliumBiO collaborates with T-NeuroDx to develop blood-based biomarkers for early detection of Alzheimer's, a significant advancement in neurodegenerative care.

Efforts include support for earlier diagnosis through LAMair™, TrilliumBiO's newly developed VEGF‑D test ROCKVILLE, Md. and CINCINNATI, June 29, 2026 /PRNewswire/ -- TrilliumBiO, a leader in biomarker discovery and precision diagnostics, today announced a commitment to raising awareness...

Oncular™ expands access to advanced molecular testing to support patient management for a rare eye cancer ROCKVILLE, Md. and ZURICH, May 12, 2026 /PRNewswire/ -- TrilliumBiO, a leader in biomarker discovery and precision diagnostics, and Oncobit, a Swiss precision oncology company, today...

Partnership will increase access to accurate monitoring of uveal melanoma, enabling personalized care and improving patient management ROCKVILLE, Md. and ZURICH, Dec. 9, 2025 /PRNewswire/ -- TrilliumBiO, a leader in biomarker discovery and precision diagnostics, today announced a...